UB Paderborn / Katalog / Suche / in CDI

1 – 17 von 17

Sortiert nach

Interleukin-2 in cancer treatment : disappointing or (still) promising ? a review

Cancer Immunology, Immunotherapy, 1993-05, Vol.36 (3), p.141-148

1993

Volltextzugriff (PDF)

Influence of p53 and bcl-2 on proliferative activity and treatment outcome in head and neck cancer patients

Oral oncology, 2000, Vol.36 (1), p.54-60

2000

Volltextzugriff (PDF)

Interleukin-2-containing liposomes : interaction of interleukin-2 with liposomal bilayers and preliminary studies on application in cancer vaccines

Pharmaceutical research, 1993-12, Vol.10 (12), p.1715-1721

1993

Volltextzugriff (PDF)

Human natural killer cells: a convenient purification procedure and the influence of cryopreservation on cytotoxic activity

Journal of immunological methods, 1993-09, Vol.165 (1), p.21-30

1993

Volltextzugriff (PDF)

The glycosylation profile of interleukin-2 activated human lymphocytes correlates to their anti-tumor activity

Anticancer research, 1996-01, Vol.16 (1), p.155

1996

Volltextzugriff (PDF)

Prognostic relevance of MIB-1 immunoreactivity, S-phase fraction, 5-bromo-2′-deoxyuridine labeling indices, and mitotic figures in gliomas

Radiation oncology investigations, 1999, Vol.7 (4), p.243-248

1999

Volltextzugriff (PDF)

Macrophages and antitumor reactions

Cancer Immunology, Immunotherapy, 1983-01, Vol.16 (2), p.67-71

1983

Volltextzugriff (PDF)

Evaluation of the VX2 rabbit auricle carcinoma as a model for head and neck cancer in humans

Journal of cranio-maxillo-facial surgery, 2000-10, Vol.28 (5), p.300-307

2000

Volltextzugriff (PDF)

Cancer treatment with interleukins 1, 4 and 6 and combinations of cytokines: a review

In vivo (Athens), 1991-11, Vol.5 (6), p.567

1991

Volltextzugriff (PDF)

Effective immunotherapy with local low doses of interleukin-2

In vivo (Athens), 1991-11, Vol.5 (6), p.561

1991

Volltextzugriff (PDF)

Acid Ethanol Fixation and Polyester Wax Embedding Combines Preservation of Antigenic Determinants with Good Morphology and Enables Simultaneous Bromodeoxyuridine (BRDU) Labeling

Biotechnic & histochemistry, 1991, Vol.66 (2), p.55-62

1991

Volltextzugriff (PDF)

Oncostatic-antibody complexes in chemotherapy

Cancer chemotherapy and pharmacology, 1980-01, Vol.4 (1), p.29-32

1980

Volltextzugriff (PDF)

Cell surface glycoconjugates as possible target structures for human natural killer cells: evidence against the involvement of glycolipids and N-linked carbohydrate chains

Glycobiology (Oxford), 1993-02, Vol.3 (1), p.69-76

1993

Volltextzugriff (PDF)

Eradication of tumour cells by successive injections of allogeneic immune and hyperimmune peritoneal cells in a murine lymphoma system

European journal of cancer, 1974-11, Vol.10 (11), p.701-706

1974

Volltextzugriff (PDF)

The success of locoregional, low-dose recombinant interleukin-2 therapy in tumor-bearing mice is dependent on the time of rIL-2 administration

Journal of experimental therapeutics & oncology, 1996-07, Vol.1 (4), p.231-236

1996

Volltextzugriff (PDF)

Membrane modifications in human erythroleukemia K562 cells during induction of programmed cell death by transforming growth factor beta 1 or cisplatin

European journal of biochemistry, 1996-10, Vol.241 (1), p.297-302

1996

Volltextzugriff (PDF)

Lymphokine-activated killer-cell-mediated killing of WiDr colon carcinoma cells is inhibited by K562 erythroleukemia cells

International immunology, 1991-10, Vol.3 (10), p.959-964

1991

Volltextzugriff (PDF)

1 – 17 von 17

Suche als RSS-Feed

Aktive Filter

ThemaHumans

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(17)
Mit Volltextzugriff
(13)

Publikationsform

Artikel
(17)

Sprache

Englisch
(17)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(14)
Science & Technology
(14)
Animals
(9)
Biological And Medical Sciences
(7)
Oncology
(7)
Medical Sciences
(6)
Immunotherapy
(5)
Mice
(5)
Neoplasms - Therapy
(5)
Tumor Cells, Cultured
(5)
Immunology
(4)
Killer Cells, Lymphokine-Activated - Immunology
(4)
Mice, Inbred Dba
(4)
Tumors
(4)
Biochemistry & Molecular Biology
(3)
Cytotoxicity, Immunologic
(3)
Female
(3)
Flow Cytometry
(3)
Interleukin-2 - Administration & Dosage
(3)

14 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Interleukin-2 in cancer treatment : disappointing or (still) promising ? a review

Influence of p53 and bcl-2 on proliferative activity and treatment outcome in head and neck cancer patients

Interleukin-2-containing liposomes : interaction of interleukin-2 with liposomal bilayers and preliminary studies on application in cancer vaccines

Human natural killer cells: a convenient purification procedure and the influence of cryopreservation on cytotoxic activity

The glycosylation profile of interleukin-2 activated human lymphocytes correlates to their anti-tumor activity

Prognostic relevance of MIB-1 immunoreactivity, S-phase fraction, 5-bromo-2′-deoxyuridine labeling indices, and mitotic figures in gliomas

Macrophages and antitumor reactions

Evaluation of the VX2 rabbit auricle carcinoma as a model for head and neck cancer in humans

Cancer treatment with interleukins 1, 4 and 6 and combinations of cytokines: a review

Effective immunotherapy with local low doses of interleukin-2

Acid Ethanol Fixation and Polyester Wax Embedding Combines Preservation of Antigenic Determinants with Good Morphology and Enables Simultaneous Bromodeoxyuridine (BRDU) Labeling

Oncostatic-antibody complexes in chemotherapy

Cell surface glycoconjugates as possible target structures for human natural killer cells: evidence against the involvement of glycolipids and N-linked carbohydrate chains

Eradication of tumour cells by successive injections of allogeneic immune and hyperimmune peritoneal cells in a murine lymphoma system

The success of locoregional, low-dose recombinant interleukin-2 therapy in tumor-bearing mice is dependent on the time of rIL-2 administration

Membrane modifications in human erythroleukemia K562 cells during induction of programmed cell death by transforming growth factor beta 1 or cisplatin

Lymphokine-activated killer-cell-mediated killing of WiDr colon carcinoma cells is inhibited by K562 erythroleukemia cells

Aktive Filter

Suchergebnisse filtern